For a comprehensive overview of the logistics, technical architecture, depth, and harmonization framework underlying the platform, please refer to the Complete360® platform page
Integrated Proteomic and Metabolomic Services Delivered Through Complete360®
Ultra-Deep. Clinically Reproducible. Translationally Ready.
Complete360® is engineered to deliver exceptional molecular depth with clinical-grade reproducibility across both body fluids and tissue. The platform is built to answer the two questions that matter most in translational science: how much biological information can be reliably captured from a single sample, and can that measurement be reproduced consistently across batches, cohorts, and time.
We operate across plasma, serum, CSF, urine, fresh tissue, FFPE, PBMCs, engineered cells, and longitudinal clinical samples under a harmonized acquisition and calibration architecture designed for stability under clinical pressure.
Depth: Seeing What Others Miss
Complete360® routinely quantifies more than 10,000 proteins per sample while preserving sensitivity for low-abundance, disease-defining biomarkers. The platform is optimized to detect proteins spanning wide dynamic ranges, including signaling molecules, immune mediators, intracellular leakage markers, and post-translational modifications. In tissue, we achieve deep coverage within complex microenvironments, resolving tumor–immune interactions and pathway activation states with structural consistency.
This depth is not incidental — it is engineered through acquisition architecture, internal calibration standards, signal optimization algorithms, and noise-suppression frameworks designed specifically for low-abundance detection. The result is expanded biological visibility without sacrificing quantitative discipline.
For metabolomics, the platform integrates targeted and pathway-resolved profiling to provide functional metabolic context alongside proteomic architecture, strengthening mechanistic interpretation and biomarker robustness.
Reproducibility: Engineered, Not Assumed
Depth without reproducibility has no clinical value. Complete360® is designed with cross-batch harmonization and longitudinal stability as core architectural principles. Standardized wet-lab workflows, controlled acquisition parameters, internal calibration systems, and AI-enabled harmonization algorithms ensure that measurements remain consistent across instruments, operators, and cohorts.
Circulating biomarkers identified in plasma can be directly validated in matched tissue under the same measurement framework, enabling systemic–tissue convergence without cross-platform variability. Longitudinal samples maintain signal stability suitable for disease monitoring, therapeutic response evaluation, and clinical trial endpoints.
Reproducibility is not evaluated post hoc — it is embedded into the acquisition architecture from the beginning.
Clinical Translation Without Rebuilding the Data
Because discovery, validation, and targeted panel development occur within the same architectural system, findings generated by Complete360® do not require reconfiguration before clinical application. The measurement framework is structured to support downstream clinical trials, biomarker qualification strategies, and regulatory documentation.
The platform’s calibration systems, harmonization methodologies, and quality control structure are engineered to align with FDA expectations for analytical validation, traceability, and reproducibility. Data generated within Complete360® is organized for direct integration into IND-enabling studies, pharmacodynamic assessments, and companion biomarker programs.
Research data does not need to be translated into a new system — it is born clinically structured.
A Platform Built for Translational Pressure
Complete360® has been validated across oncology, immunotherapy, and complex disease cohorts where sensitivity, stability, and longitudinal comparability are non-negotiable. The system compounds over time: each cohort strengthens calibration accuracy, expands biological reference depth, and increases cross-study harmonization power. When evaluating proteomics and metabolomics partners, the question is not simply how many proteins can be detected, but how deeply and how consistently they can be measured across real clinical conditions. Complete360® is built to deliver both.